Drug Safety alert: CDSCO flags 78 drug samples
In its latest drug safety alert, the apex drug regulatory body, Central Drug Standard Control Organisation (CDSCO) has flagged 78 medicine batches for failing to qualify for a random drug sample test for December– 2023.
These include Montelukast Sodium and Levocetirizine Dihydrochloride Tablets manufactured by Bonsai Pharma, Multi-Vitamin Tablets (VITAJACKS-S TABLETS) manufactured by Jackson Laboratories, Telmisartan and Amlodipine Tablets IP (Zensartan-AM Tablets) manufactured by Windlass Biotech Limited, Telmisartan Tablets IP 40 mg (Telmibeck-40 Tablets) manufactured by Biocore Pharmaceuticals, Pregabalin Capsules IP (Pragavir Capsules) manufactured by Mayoford Pharma.
For the full story, check out the link given below:
CDSCO Drug Alert: 78 Drug Samples Including Alkem's Pan 40 Flagged
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd